At Alder we work closely with investigators and trial participants to advance our antibody therapeutics into the clinic. Our goal is to discover new medical options that meet the profound needs of patients. Participants in our trials play a key role by contributing to our understanding of disease pathologies, and demonstrating how potential new therapies can improve treatment options.
Current Clinical Trials
ALD403-CLIN-006 (Phase 3)
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Frequent Episodic Migraine (Promise I). To learn more about this study or to see if you qualify, visit The Promise Study.
ALD403-CLIN-005 (Phase 2)
A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients with Chronic Migraine.
To learn more about Alder’s current clinical trials, please visit www.clinicaltrials.gov.